WOBURN, Mass.--(EON: Enhanced Online News)--CryoXtract Instruments, LLC, a leader in developing unique automation solutions for preserving and optimizing frozen biological samples, reached a non-exclusive global co-marketing agreement with Wheaton Industries, Inc. that will provide the worldwide scientific community with a unique set of solutions for optimally storing, preserving and accessing valuable frozen tissue samples.
“The co-marketing agreement with CryoXtract further leverages our expertise in cryopreservation with breakthrough technology to answer the biomedical research community’s demand for repeated access to their frozen tissue samples, which is expected to play an increasingly crucial role for important research and development”
CryoXtract recently introduced its second commercial product, the CXT 350, to provide the scientific community multiple access to valuable frozen tissue samples while preserving the frozen state of both the parent sample and cored aliquots throughout the process. This unique solution allows multiple access to highly valuable frozen tissue samples while preserving the integrity of the parent biospecimen, thereby resulting in optimized sample usage and higher quality scientific outcomes.
WHEATON, a global leader in biosample storage solutions, recently introduced its much-anticipated and unique CryoELITE® Tissue Vial product line, which allows the scientific community to store highly valuable tissue samples in industry-standard configurations. WHEATON’s 125 years of proprietary knowledge, design experience and manufacturing expertise led to the development of such an important new product line whose unique attributes include a wide-mouth opening, 5mL capacity, high-integrity closure, freestanding design and a textured external surface to facilitate grip and promote clear, legible marking. The CryoELITE® Tissue Vial offers researchers who work with biological tissue sections ease of use, convenience and security.
Together, the two companies will market a unique solution that now allows the scientific community to efficiently access highly valuable frozen tissue through CryoXtract’s proprietary CXT 350 platform and store samples and aliquots in WHEATON’s new CryoELITE® Tissue Vial, as well as other storage media. Additionally, the companies expect their joint efforts to accelerate their current commercial plans while progressing efforts to adopt important best-practice standards throughout the industry.
Currently, frozen tissue samples are stored in a myriad of different, inefficient and non-standard formats that lead to highly inefficient operational issues, and more importantly, questionable sample integrity that can negatively impact important downstream scientific research and development. It is estimated that over one billion frozen tissue biosamples are currently stored throughout the scientific community with no standardization across storage media or adoption of best-practice standards. Demand for improved storage conditions will only increase as double-digit annual growth in tissue collection and storage is projected to continue for the foreseeable future.
“Given the rapidly accelerating advances across all major scientific initiatives today, the importance of creating and implementing industry standards for optimal sample storage and retrieval has never been greater,” said John A. McCarthy, Jr., CryoXtract CEO. “Our co-marketing agreement with WHEATON produces a unique and important solution for standardizing frozen tissue storage and enabling the scientific community to access and re-access frozen tissue samples for critical research and development.”
“WHEATON has a long history of providing the scientific community with unique solutions to help our customers solve problems, and our CryoELITE® Tissue Vials were developed in response to these pressing customer needs,” said Wayne L. Brinster, CEO & President of WHEATON. “The co-marketing agreement with CryoXtract further leverages our expertise in cryopreservation with breakthrough technology to answer the biomedical research community’s demand for repeated access to their frozen tissue samples, which is expected to play an increasingly crucial role for important research and development,” he added. “Partnering with an innovative and complementary solutions-oriented company like CryoXtract now provides us both greater distribution leverage and a unique joint product offering to address critical customer needs across the global scientific marketplace.”
CryoXtract’s new CXT 350 product line complements the company’s flagship CXT 750 for large-scale automated access to frozen biofluids, providing the scientific community with a portfolio of solutions for accessing frozen biosamples while preserving the integrity of the parent biospecimen. The International Society for Biological and Environmental Repositories (ISBER) recently awarded its prestigious Outstanding New Product Award to the company’s CXT 750 Frozen Sample Aliquotter.
“We’re very pleased to see the rapid commercial progress CryoXtract continues to make, and look forward to the leverage that we believe both WHEATON and CryoXtract provide each other with this important co-marketing partnership,” said Dr. Omar Amirana, Managing Director and Head of Life Sciences at Allied Minds, Inc., the Boston-based private investment group that founded and funds CryoXtract.
About CryoXtract Instruments, LLC
CryoXtract is the leading developer of unique automation solutions that allow for the retrieval of multiple frozen samples from a single frozen biosample without exposing the source sample to the deleterious biological impact from freeze/thaw cycling. The company’s novel automation technology platform improves frozen biosample processing, protects the viability of frozen biosamples after cores have been extracted, improves lab efficiencies and economics, and helps optimize scientific outcomes.
CryoXtract is a subsidiary of Allied Minds, Inc., a Boston-based private investment corporation. For more information, please visit www.cryoxtract.com.
About Allied Minds, Inc.
Allied Minds is a U.S. investment firm that deploys private equity to form, fund, manage and build start-ups based on early-stage technologies developed at renowned U.S. universities and federal research institutions. Allied Minds serves as a diversified holding company that supports its businesses with capital, management and shared services, and is the premier investment firm to utilize this novel and fully integrated approach for technology commercialization. More information about the Boston-based company can be found at www.alliedminds.com.
Throughout its 125 year history, WHEATON has been dedicated to supporting scientific advances and discovery by providing innovative solutions for the laboratory research, diagnostic and specialty pharmaceutical industries. The company’s expertise in plastic and glass containers, coupled with a wide selection of closure systems and custom solutions, ensures the secure storage and delivery of science’s most sensitive materials and precious specimens. For more information, please visit www.wheaton.com.